Exploring Aerosol Absorption in Humans: Pharmacokinetics of Monodisperse Fluticasone Propionate
Usmani OS.
Respiratory Drug Delivery 2014. Volume 1, 2014: 155-162.
Abstract:
Drug particle size influences the lung deposition and systemic bioavailability of inhaled aerosols. We investigated the fate of different particle sizes of inhaled fluticasone propionate (FP) in the lungs of asthmatic patients. Each subject inhaled four treatments in a single-dose, randomized, crossover manner; FP-50 μg monodisperse particle sizes of 1.5, 3, and 6 μm and also FP-250 μg polydisperse pMDI + spacer (2.8 μm). Smaller particles (1.5, 3 μm) achieved significantly (p<0.05) higher peak concentrations (Cmax) and showed greater systemic absorption (AUC0-12h) compared to larger particles (6μm) and pMDI aerosol. The systemic bioavailability of inhaled FP is related to drug particle size, the total lung dose and the regional deposition of the lung dose.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
